10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel hypoglycemic agents which reduce reabsorption of glucose at the renal proximal tubule, resulting in significant glycosuria and increased risk of genital mycotic infections (GMI). These infections are typically not severe as reported in large systematic reviews and meta-analyses of the medications. These reviews have also demonstrated significant cardiovascular benefits through other mechanisms of action, making them attractive options for the management of Type 2 diabetes mellitus (T2DM). We present two cases with underlying abnormalities of the urogenital tract in which the GMI were complicated and necessitated cessation of the SGLT2 inhibitor.

          Case presentations

          Both cases are patients with T2DM on empagliflozin, an SGLT2 inhibitor. The first case is a 64 year old man with Candida albicans balanitis and candidemia who was found to have an obstructing renal calculus and prostatic abscess requiring operative management. The second case describes a 72 year old man with Candida glabrata candidemia who was found to have prostatomegaly, balanitis xerotica obliterans with significant urethral stricture and bladder diverticulae. His treatment was more complex due to fluconazole resistance and concerns about urinary tract penetration of other antifungals. Both patients recovered following prolonged courses of antifungal therapy and in both cases the SGLT2 inhibitor was ceased.

          Conclusions

          Despite their cardiovascular benefits, SGLT2 inhibitors can be associated with complicated fungal infections including candidemia and patients with anatomical abnormalities of the urogenital tract may be more susceptible to these infections as demonstrated in these cases. Clinicians should be aware of their mechanism of action and associated risk of infection and prior to prescription, assessment of urogenital anatomical abnormalities should be performed to identify patients who may be at risk of complicated infection.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

          The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

            Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

              It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
                Bookmark

                Author and article information

                Contributors
                caroline.bartolo@barwonhealth.org.au
                victoria.hall@uhn.ca
                Journal
                BMC Infect Dis
                BMC Infect Dis
                BMC Infectious Diseases
                BioMed Central (London )
                1471-2334
                20 March 2021
                20 March 2021
                2021
                : 21
                : 284
                Affiliations
                [1 ]GRID grid.414257.1, ISNI 0000 0004 0540 0062, Department of Infectious Diseases, , Barwon Health, ; Geelong, Victoria Australia
                [2 ]GRID grid.1623.6, ISNI 0000 0004 0432 511X, Department of Infectious Diseases, , Alfred Hospital, ; Melbourne, Victoria Australia
                [3 ]GRID grid.1002.3, ISNI 0000 0004 1936 7857, Monash University, ; Melbourne, Victoria Australia
                [4 ]GRID grid.1021.2, ISNI 0000 0001 0526 7079, Deakin University, ; Melbourne, Victoria Australia
                Author information
                http://orcid.org/0000-0001-8258-414X
                Article
                5982
                10.1186/s12879-021-05982-3
                7980614
                33743624
                9303cd90-7b06-4880-9ceb-e0cff2b04583
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 21 December 2020
                : 11 March 2021
                Categories
                Case Report
                Custom metadata
                © The Author(s) 2021

                Infectious disease & Microbiology
                candidemia,sglt2 inhibitor,glycosuria,case report,genital mycotic infection,prostatic abscess

                Comments

                Comment on this article